Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Medicenna Therapeutics Corp ( (TSE:MDNA) ) has provided an update.
Medicenna Therapeutics Corp announced its financial results for the third quarter of fiscal 2025, highlighting significant progress in its ABILITY-1 trial, which combines MDNA11 with KEYTRUDA. The trial demonstrated a 78% disease control rate with promising responses, including complete and partial responses in patients with treatment-refractory tumors. The company also reported strong financial backing, ensuring operations are funded through mid-2026, and shared its excitement about upcoming milestones that could further validate its clinical development program.
More about Medicenna Therapeutics Corp
Medicenna Therapeutics Corp is a clinical-stage immunotherapy company focused on developing Superkines, which are advanced therapeutics designed to improve the immune system’s ability to fight cancer. The company operates in the biotechnology industry and is targeting a range of tumor types with its innovative therapies.
YTD Price Performance: -20.13%
Average Trading Volume: 67,432
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$99.33M
For a thorough assessment of MDNA stock, go to TipRanks’ Stock Analysis page.